Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents-Reference-Cited by-同舟云学术

Hypomethylating agents in myelodysplastic syndromes changing the inevitable: the value of azacitidine as maintenance therapy, effects on transfusion and combination with other agents

Published:2009-12 Issue: Volume:33 Page:S18-S21
ISSN:0145-2126
Container-title:Leukemia Research
language:en
Short-container-title:Leukemia Research

Author:

Silverman Lewis R.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference25 articles.

1. Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the Cancer and Leukemia Group B;Silverman;J Clin Oncol,2002

2. The modulating effect of azacitidine (Aza C) on the cytogenetically tracked MDS clone impact survival;Najfeld;Blood,2004

3. Targeting hypomethylation of DNA to achieve cellular differentiation in myelodysplastic syndromes (MDS);Silverman;Oncologist,2001

4. Bioavailability of azacitidine subcutaneous versus intravenous in patients with the myelodysplastic syndromes;Marcucci;J Clin Pharmacol,2005

5. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study;Fenaux;Lancet Oncol,2009

Cited by 12 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of azacitidine in elderly patients with intermediate to high-risk myelodysplastic syndromes;Therapeutic Advances in Hematology;2016-10-22

2. Current Current and novel therapeutic approaches in myelodysplastic syndromes;The Journal of Community and Supportive Oncology;2014-07-01

3. Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes;Cytometry Part B: Clinical Cytometry;2014-01-28

4. The role of hypomethylating agents in myelodysplastic syndrome: changing the management paradigm;Expert Review of Hematology;2013-12

5. The Role of Human Equilibrative Nucleoside Transporter 1 on the Cellular Transport of the DNA Methyltransferase Inhibitors 5-Azacytidine and CP-4200 in Human Leukemia Cells;Molecular Pharmacology;2013-06-28